The vasa vasorum and the paradox of beta-blocker therapy.
The use of beta-blockers in the treatment of angina, claudication or hypertension is a therapeutic paradox. All those conditions feature increased constrictor tone, so it appears to make little sense to treat them with drugs which block the action of vasodilators. The paradox would disappear, however, if vasodilators could be shown to have the ability to increase constrictor tone in certain circumstances. This paper argues that they have. It presents evidence that isoprenaline, a potent dilator of the dog's saphenous vein, is a powerful constrictor of the vein when it is released from the vasa vasorum of the vein. Indeed, on a molar basis, it appears to be a more powerful constrictor of the vein than exogenous noradrenaline is. Since there is no reason to suppose that isoprenaline is unique among dilators in demonstrating this type of bimodal behaviour, it is possible to justify the proposal that compounds which are normally classified as endogenous dilators may, when released from the pathological vasa vasorum which neoproliferate in atherosclerosis, be responsible for the constrictor effects associated with claudication, and some forms of hypertension and angina. If true then beta-blockade would not be a paradoxical choice of treatment for those conditions.
Anatomy Department, University College, Cork, Ireland.
T P
TP
Crotty
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D004285:Dogs; D007545:Isoproterenol / Q000494:pharmacology; D008954:Models, Biological; D009638:Norepinephrine / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D012501:Saphenous Vein / Q000187:drug effects / Q000502:physiology; D014651:Vasa Vasorum / Q000187:drug effects* / Q000502:physiology; D014661:Vasoconstriction / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D011942:Receptors, Adrenergic, alpha; D007545:Isoproterenol; D009638:Norepinephrine